Menlo Therapeutics, Inc.
BalancedMNLO·US·🇺🇸 US
53%buys·47%sells
502 transactions$71.8MTotal buys·27 buys
$38.9MTotal sells·24 sells
4040 insiders
Last: Dec 12, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 12, 25 | BARBARI SHARON SURREY | Grant | - | |
| Dec 12, 25 | Basta Steven L | Grant | - | |
| Dec 12, 25 | LEPORE PATRICK G | Grant | - | |
| Dec 12, 25 | Sandoval Elisabeth | Grant | - | |
| Sep 30, 25 | Domzalski David | Other | $4K | |
| Sep 30, 25 | Harsch Mutya | Other | $1K | |
| Sep 30, 25 | Stuart Iain | Other | $834 | |
| Sep 30, 25 | Zeronda Tyler | Other | $1K | |
| Jun 30, 25 | Domzalski David | Other | $21K | |
| Jun 30, 25 | Harsch Mutya | Other | $6K |
Menlo Therapeutics, Inc. (MNLO) has recorded 502 insider transactions from 40 insiders. Total insider buying volume stands at $71.8M, while total selling volume is $38.9M. Insider activity shows a balanced mix of buying and selling.
Menlo Therapeutics, Inc. (MNLO) has recorded 502 insider operations, including 27 open-market purchases ($71.8M), 24 sales ($38.9M) and 451 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is balanced.
Menlo Therapeutics, Inc. shows moderate insider activity with 6 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Domzalski David (CEO), Basta Steven L (CEO) & Saik Andrew (CFO), with respectively 92, 65, 46 transactions.
Across all 502 recorded transactions, the breakdown by type is: grant (210, 42%), exercise (134, 27%), tax (101, 20%), buys (27, 5%), sells (24, 5%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Menlo Therapeutics, Inc. has recorded 502 insider operations in total, including 27 open-market purchases ($71.8M), 24 sales ($38.9M) and 451 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 12, 2025.
Insiders at Menlo Therapeutics, Inc. show balanced activity with 53% purchases and 47% sales. Total buy volume is $71.8M versus $38.9M in sales.
InsiderLens tracks 40 insiders at Menlo Therapeutics, Inc. (MNLO). Domzalski David (CEO, 92 tx), Basta Steven L (CEO, 65 tx), Saik Andrew (CFO, 46 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for MNLO is neutral, based on a 53% buy ratio across 51 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Menlo Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.